Zinc fingers to touch Gilead therapies | March 5, 2018 Issue - Vol. 96 Issue 10 | Chemical & Engineering News
Volume 96 Issue 10 | p. 11 | Concentrates
Issue Date: March 5, 2018

Zinc fingers to touch Gilead therapies

By Ryan Cross
Department: Business
Keywords: Biotechnology, gene editing, Sangamo, Gilead, ZFN, zinc finger nuclease, CRISPR

Gilead Sciences is betting big on gene editing to improve its cell immunotherapy programs. But rather than embrace CRISPR, Gilead has partnered with Sangamo Therapeutics, a pioneer of an older gene-editing tool called the zinc finger nuclease (ZFN). Sangamo has amassed a large ZFN protein library, allowing it to link ZFNs together to target any site in the genome. Gilead will give Sangamo $150 million up front and up to $3 billion more if Gilead develops 10 or more new therapies.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment